5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress

Prince MJ. World Alzheimer Report 2016—improving healthcare for people living with dementia: coverage, quality and costs now and in the future. https://www.alz.co.uk/research/world-report-2016 . Accessed 9 Mar 2018.

Ramirez MJ. 5-HT6 receptors and Alzheimer’s disease (5-hydroxytryptamine 6) (report). Alzheimers Res Ther. 2013;5:15.

Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.

Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin Drug Saf. 2004;3:425–40.

Nirogi R, Shinde A, Kambhampati RS, et al. Discovery and development of 1-(2-bromophenyl)sulfonyl-5-methoxy-3-(4-methyl-1-piperazinyl)methyl-1H-indole dimesylate monohydrate (SUVN-502): a novel, potent, selective and orally active serotonin 6 (5-HT) receptor antagonist for potential treatment of Alzheimer’s disease. J Med Chem. 2017;60:1843.

Ferrero H, Solas M, Francis PT, Ramirez MJ. Serotonin 5-HT receptor antagonists in Alzheimer’s disease: therapeutic rationale and current development status. CNS Drugs. 2017;31:19.

Mohler E, Baker P, Gannon K, Jones S, Shacham S, Sweeney J, Ragozzino M. The effects of PRX-07034, a novel 5-HT 6 antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology. 2012;220:687–96.

Halford J, Harrold J, Boyland E, Lawton C, Blundell J. Serotonergic drugs. Drugs. 2007;67:27–56.

Ivachtchenko AV, Okun IM, Ivanenkov YA, Veselove MS. AVN-322 is a safe orally bio-available potent and highly selective antagonist of 5-HT6R with demonstrated ability to improve impaired memory in animal models. Curr Alzheimer Res. 2017;14:268–94.

Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: a multi-target drug candidate for the treatment of CNS disorders. J Alzheimer’s Dis. 2016;53:583–620.

Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA. AVN-211, novel and highly selective 5-HT6 receptor small molecule antagonist, for the treatment of Alzheimer’s disease. Mol Pharm. 2016;13:945.

Pfizer. Study evaluating the safety and efficacy of PF-05212377 or placebo in subjects with Alzheimer’s disease with existing neuropsychiatric symptoms on donepezil. https://clinicaltrials.gov/ct2/show/NCT01712074 . Accessed 10 Feb 2018.

Schneider LS. Idalopirdine for Alzheimer’s disease: written in the stars. Lancet Neurol. 2014;13:1063–5.

Bennett DA. Lack of benefit with idalopirdine for Alzheimer disease: another therapeutic failure in a complex disease process. JAMA. 2018;319:123.

Hesselink JMK. Idalopirdine in Alzheimer disease: never change a winning team and do not build exclusively on surrogates. Lessons learned from drug development trials. J Pharmacol Clin Res. 2017;2:1.

Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA. 2018;319:130.

Maher-Edwards M, Zvartau-Hind AJ, Hunter M, Gold G, Hopton G, Jacobs M Davy, Williams P. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimers disease. Curr Alzheimer Res. 2010;7:374–85.

Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011;26:536–44.

Maher-Edwards G, Watson C, Ascher J, et al. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2015;1:23–36.

Axovant Sciences Ltd. 12-Month open-label extension study of intepirdine (RVT-101) in subjects with Alzheimer’s disease: MINDSET extension—full text view. https://clinicaltrials.gov/ct2/show/NCT02586909 . Accessed 10 Feb 2018.

Sweetlove M. Phase III CONCERT trial of latrepirdine. Pharm Med. 2012;26:113–5.

Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207–15.

Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Jasti V. Safety, tolerability and pharmacokinetics of SUVN-502—a 5-HT6 receptor antagonist, first in human phase-1 Single Ascending Dose (SAD) study. Alzheimer’s Dement. 2009;5:P250.

Suven Life Sciences Limited. SUVN-502 with donepezil and memantine for the treatment of moderate Alzheimer’s disease—phase 2a study. https://clinicaltrials.gov/ct2/show/NCT02580305 . Accessed 10 Feb 2018.

Nirogi R, Ajjala DR, Aleti R, Rayapati L, Pantangi HR, Boggavarapu RK, Padala NSP. Development and validation of sensitive LC–MS/MS method for the quantification of SUVN-502 and its metabolite and its application for first in human pharmacokinetic study. J Pharm Biomed Anal. 2017;145:423–30.

Cirrito JR, Disabato BM, Restivo JL, et al (2011) Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 2011;108:14968–73.